djbombsquad
Board Sponsor
What is the difference? I have tamoxifen and looking to get some letrozole.
djbombsquad; said:What is the difference? I have tamoxifen and looking to get some letrozole.
AKA Letro is an aromatase inhibitor and Tamox is a SERM.
This might help:
Study Confirms Letrozole Better than Tamoxifen
Likely a Better Option for Advanced Breast Cancer
Article date: 2003/06/17
Tamoxifen has been the standard form of hormonal therapy used to treat advanced breast cancer for more than two decades. But newer drugs called aromatase inhibitors are proving to be just as good, if not better than, tamoxifen.
New study results reported in the Journal of Clinical Oncology (Vol. 21, No. 11: 2101-2109) now confirm the superiority of one of these drugs, letrozole (Femara), over tamoxifen in cancer that is locally advanced or has spread to other parts of the body.
Breast Cancer and Hormones
Most breast cancers grow in response to levels of estrogen in the body. Estrogen is a �female� hormone that signals breast cells to grow by attaching to specific proteins called receptors on their outer surfaces. Tamoxifen, which first came into use in the 1970s, works by blocking these estrogen receptors, preventing estrogen from attaching to them. It has proven to be effective in prolonging survival in women with advanced breast cancer who have many estrogen receptors on their cells. (These cancers are considered to be �estrogen receptor positive.�) In almost all women with advanced cancer, however, tamoxifen eventually stops working.
Scientists developed aromatase inhibitors to help women with breast cancer for whom tamoxifen does not work or is no longer working. These drugs function by preventing estrogen from being produced in the first place, but they are only effective in women who are past menopause. (These women�s bodies are no longer producing large amounts of estrogen on their own.)
Three modern versions of aromatase inhibitors � letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin) are FDA approved for use in breast cancer when tamoxifen is no longer effective.
Since these drugs worked so well in women no longer responding to tamoxifen, doctors wondered if they would be better than tamoxifen if used initially. Researchers attempted to answer this question regarding letrozole in the current study, begun in 1996.
Letrozole versus Tamoxifen
The newly published results are actually an update of study findings first published two years ago. This study was the key to the FDA approving letrozole for use as first-line therapy for advanced beast cancer in 2001.
In this multinational clinical trial, more than 900 postmenopausal women with advanced breast cancer were assigned to take a daily pill consisting either of tamoxifen or letrozole. None of the women knew which pill they were taking, but they could be crossed over (switched) to the other form of therapy if the initial one stopped working. The average time on the study for these women was 32 months.
The women taking letrozole were more likely to have their tumors shrink by at least half than those taking tamoxifen (32% vs. 21%), and were more likely to have at least some period of time when the cancer did not grow (50% vs. 38%).
Those taking letrozole also had a longer average period of time before the cancer progressed (9.4 months vs. 6 months) and were able to take the hormonal therapy longer (16.3 months vs. 9.3 months). They had a longer period of time before the disease affected their everyday functioning, as well.
Women taking letrozole had a slightly longer average survival time (34 months vs. 30 months), but these numbers were close enough that the difference may have been due to chance. Fewer women on the letrozole arm appeared to die early (in the first two years of the study), however.
The researchers pointed out that while the survival difference was not statistically significant, it was likely influenced by the fact that about half the women on each study arm crossed over to the other form of therapy. This meant that about half of the women overall eventually received both letrozole and tamoxifen, which would tend to make the survival results similar for both arms.
Results Promising, But More Data Will Be Key
Overall, however, most of the study results still favored using letrozole over tamoxifen in this situation.
�The consistency of the results in this trial supports the use of letrozole as superior first-line [hormonal] therapy compared with tamoxifen in postmenopausal women with hormone-sensitive advanced breast cancer,� the authors conclude.
It is not clear whether the study will immediately change the way doctors treat their breast cancer patients, however. One reason for this is that there is more than two decades� worth of data backing tamoxifen use in advanced breast cancer, while the data supporting letrozole is only a few years old. Doctors may feel that more studies, exploring both the benefits and risks of the new drug, will be needed to cause a true change in practice.
Still, the results are promising, and may lead women and their doctors to consider letrozole as an effective option in treating advanced breast cancer.
ACS News Center stories are provided as a source of cancer-related news and are not intended to be used as press releases.
So tamo blocks new estro and letro shuts down existing estro? That is what I am getting at.
Tamoxifen blocks estrogen at tissue specific sites (eg breasts), while letro enhibits the enzyme that converts test to estrogen. Letro is not for post cycle therapy, but can be used on cycle to reduce estrogen related sides, or could be used treat gyno if it pops up after a cycle. Letro is extremely powerful, and needs to be used properly to avoid any estrogen up-surge after its discontinued. So, if you state your intended use for these drugs, someone may be able to help you out.
That sounds somewhat confusing...
Letro is not for post cycle therapy...yet it can be used to treat gyno if it pops up after a cycle.
So what you're saying is, alone, Letro is not a sufficient PCT coming off a cycle like a SERM is...but if one were to experience gyno after a cycle, throwing in some Letro (while on PCT, or after PCT) would be okay?
Well, I've seen guys use it for post cycle therapy before because it does boost test levels by raising LH, FSH, and SHBG. The problem is that is erraticates your body of estrogen to undetectable levels, which is not a good thing. Small levels of est in the male body are nessesary for numerous things, not to mention the rebound effect from est. being this low. SERMS do not have this est. deleting effect...at all. They just block estrogen at the receptor, as your body works to restore a normal test to est ratio. Does this make sense?
yea it does...so if someone were to run Letro after post cycle therapy, they would almost need to followup with a small dose of a SERM to help combat estro rebound?
I am thinking
staying at .1mg every other day.
----------------------------------------------------------------------------
0.02 mg of Letrozole increased testosterone by 45% after 2 days
0.1 mg of Letrozole increased testosterone by 49% after 2 days
0.5 mg of Letrozole increased testosterone by 48% after 2 days
1 mg of Letrozole increased testosterone by 41% after 2 days
2.5 mg of Letrozole increased testosterone by 74% after 3 days
10 mg of Letrozole increased testosterone by 97% after 2 days
30 mg of Letrozole increased testosterone by 113% after 3 days
Its only confusing if you do not really know what the reason for proper PCT. You are mistaken a common side effect, gyno, as the primary reason for use of a SERM for PCT. Gyno is the result of imbalanced hormone levels. Start with the SERM, if you have tell tale signs of the start of gyno i.e. itchy swollen nipples then add 1.25mg/letro EOD in conjuction with SERM.That sounds somewhat confusing...
Letro is not for post cycle therapy...yet it can be used to treat gyno if it pops up after a cycle.
So what you're saying is, alone, Letro is not a sufficient PCT coming off a cycle like a SERM is...but if one were to experience gyno after a cycle, throwing in some Letro (while on PCT, or after PCT) would be okay?